These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1965077)

  • 1. Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers.
    Wiedermann G; Ambrosch F; Kollaritsch H; Hofmann H; Kunz C; D'Hondt E; Delem A; André FE; Safary A; Stéphenne J
    Vaccine; 1990 Dec; 8(6):581-4. PubMed ID: 1965077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine.
    Green MS; Cohen D; Lerman Y; Sjogren M; Binn LN; Zur S; Slepon R; Robin G; Hoke C; Bancroft W
    Isr J Med Sci; 1994; 30(5-6):485-8. PubMed ID: 8034508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings.
    André FE; D'Hondt E; Delem A; Safary A
    Vaccine; 1992; 10 Suppl 1():S160-8. PubMed ID: 1335652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine.
    Theilmann L; Kallinowski B; Gmelin K; Hofmann F; Scheiermann N; Wohland B; Stickl H; Maiwald H; Moriabadi FK; Bock HL
    Vaccine; 1992; 10 Suppl 1():S132-4. PubMed ID: 1335644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence.
    Van Damme P; Thoelen S; Cramm M; De Groote K; Safary A; Meheus A
    J Med Virol; 1994 Dec; 44(4):446-51. PubMed ID: 7897379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis A vaccination: schedule for accelerated immunization.
    Müller R; Chriske H; Deinhardt F; Jilg J; Theilmann L; Hess G; Hofmann F; Hopf U; Stickl H; Maiwald H
    Vaccine; 1992; 10 Suppl 1():S124-5. PubMed ID: 1335641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study.
    Goilav C; Zuckerman J; Lafrenz M; Vidor E; Lauwers S; Ratheau C; Benichou G; Zuckerman A
    J Med Virol; 1995 Jul; 46(3):287-92. PubMed ID: 7561805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of hepatitis A vaccine in healthy adult volunteers.
    Horng YC; Chang MH; Lee CY; Safary A; Andre FE; Chen DS
    J Gastroenterol Hepatol; 1993; 8(4):338-41. PubMed ID: 8397010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals.
    Davidson M; Krugman S; Sandman LA
    Vaccine; 1992; 10 Suppl 1():S119-20. PubMed ID: 1335639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the reactogenicity and immunogenicity of two different dose levels of hepatitis A vaccine in healthy children and adolescents.
    Poovorawan Y; Kosuwon P; Sutra S; Theamboonlers A; Vimolket T; Safary A
    Asian Pac J Allergy Immunol; 1998; 16(2-3):111-7. PubMed ID: 9876949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hepatitis A vaccination schedules on immune response.
    Tilzey AJ; Palmer SJ; Barrow S; Perry KR; Tyrell H; Safary A; Banatvala JE
    Vaccine; 1992; 10 Suppl 1():S121-3. PubMed ID: 1335640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children.
    Kanra G; Yalçin SS; Ceyhan M; Yurdakök K
    Turk J Pediatr; 2000; 42(2):105-8. PubMed ID: 10936974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine.
    Goubau P; Van Gerven V; Safary A; Delem A; Knops J; D'Hondt E; André FE; Desmyter J
    Vaccine; 1992; 10 Suppl 1():S114-8. PubMed ID: 1335638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease.
    Lee SD; Chan CY; Yu MI; Wang YJ; Chang FY; Lo KJ; Safary A
    J Med Virol; 1997 Jun; 52(2):215-8. PubMed ID: 9179771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin.
    Green MS; Cohen D; Lerman Y; Sjogren M; Binn LN; Zur S; Slepon R; Robin G; Hoke C; Bancroft W
    J Infect Dis; 1993 Sep; 168(3):740-3. PubMed ID: 8394864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous active and passive immunization against hepatitis A studied in a population of travellers.
    Wagner G; Lavanchy D; Darioli R; Pécoud A; Brulein V; Safary A; Frei PC
    Vaccine; 1993; 11(10):1027-32. PubMed ID: 8212822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactogenicity and immunogenicity of inactivated hepatitis A vaccines.
    Just M; Berger R
    Vaccine; 1992; 10 Suppl 1():S110-3. PubMed ID: 1362031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A.
    Ellerbeck EF; Lewis JA; Nalin D; Gershman K; Miller WJ; Armstrong ME; Davide JP; Rhoad AE; McGuire B; Calandra G
    Vaccine; 1992; 10(10):668-72. PubMed ID: 1523877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous passive and active immunization against hepatitis A.
    Leentvaar-Kuijpers A; Coutinho RA; Brulein V; Safary A
    Vaccine; 1992; 10 Suppl 1():S138-41. PubMed ID: 1335646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule.
    Westblom TU; Gudipati S; DeRousse C; Midkiff BR; Belshe RB
    J Infect Dis; 1994 May; 169(5):996-1001. PubMed ID: 8169430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.